Therapy Areas: Diabetes
Tilak Healthcare Forges Partnership for Co-Promotion with Novartis France
17 May 2019 - - French video game studio Tilak Healthcare has inked an exclusive co-promotion partnership with Swiss pharmaceutical company Novartis' (SIX: NOVN) (NYSE: NVS) Novartis France busin...
Exelixis' Collaborator Daiichi Sankyo Launches Minnebro Tablets in Japan
17 May 2019 - - US-based biotechnology company Exelixis, Inc.'s (NASDAQ: EXEL) partner, Japan-based Daiichi Sankyo Company, Ltd. has launched Minnebro (esaxerenone) tablets as a treatment for pat...
Melior Pharmaceuticals' reports results of phase 2b trial of Tolimidone for Type two diabetes mellitus
17 May 2019 - United States-based Melior Pharmaceuticals' insulin sensitiser, tolimidone (MLR-1023), has succeeded in a phase 2b trial in Type two diabetes mellitus (T2DM), it was reported yester...
Vivimed Life Sciences Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid Impurity
15 May 2019 - - India-based Vivimed Life Sciences Pvt Ltd is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level due to the detection of N-Nitroso-N-methyl-4...
Dance Biopharm Names Lee to Board of Directors
15 May 2019 - - US-based clinical stage biopharma company Dance Biopharm Holdings, Inc has appointed Kenneth B. Lee, Jr. to its board of directors, the company said.

He will also serve as...
Zealand Pharma reports achievement of primary and all key secondary endpoints in confirmatory phase 3 trial with dasiglucagon for severe hypoglycaemia
15 May 2019 - Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Tuesday successful resul...